JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease

Overview

The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are central mediators of cellular stress responses in Parkinson’s disease. These kinases drive dopaminergic neuron death through apoptosis, microglial activation, and neuroinflammation. Multiple companies are actively developing inhibitors and modulators targeting these pathways for neuroprotection in PD.

The scientific rationale is strong: JNK3 (MAPK10) is neuron-specific and mediates dopaminergic apoptosis, while p38α (MAPK14) drives microglial pro-inflammatory cytokine production. Both pathways are activated by common PD stressors including mitochondrial dysfunction, oxidative stress, and alpha-synuclein aggregation. ^{1c-Jun N-terminal kinase pathway in Parkinson's disease: mechanisms and therapeutic targeting2024 · PMID 38488654Open reference2p38 MAPK in neuroinflammation and neurodegeneration: a druggable target?2024 · PMID 38212980Open reference}

Competitive Landscape

flowchart LR
    subgraph JNK_Inhibitors
        A1["CEP-1347\n(Fenebrutinib/Genentech)"]
        A2["SP600125\n(Preclinical)"]
        A3["JNK-IN-8\n(Preclinical)"]
        A4["AAV-JNK3 shRNA\n(Gene therapy)"]
    end

    subgraph p38_Inhibitors
        B1["Losmapimod\n(Fulcrum)"]
        B2["PH-797804\n(Preclinical)"]
        B3["SB239063\n(Preclinical)"]
        B4["VX-745\n(Preclinical)"]
    end

    subgraph Dual_Modulators
        C1["C21\n(Vicore - AT2/JNK)"]
        C2["FUL-20002\n(Fulcrum - p38/JNK)"]
        C3["Dual inhibitors\n(Preclinical)"]
    end

    A1 --> D["Dopaminergic\nNeuroprotection"]
    A2 --> D
    A3 --> D
    A4 --> D
    B1 --> E["Microglial\nInhibition"]
    B2 --> E
    B3 --> E
    B4 --> E
    C1 --> F["Combined\nNeuroprotection"]
    C2 --> F
    C3 --> F

    style D fill:#bbf,stroke:#333
    style E fill:#bbf,stroke:#333
    style F fill:#bbf,stroke:#333

Company Profiles

1. Fulcrum Therapeutics

Overview: Fulcrum Therapeutics (NASDAQ: FULC) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing small molecule therapeutics targeting genetically defined diseases. The company’s lead program is losmapimod, a selective p38α/β MAPK inhibitor that has demonstrated neuroprotective effects in preclinical models and is currently in clinical trials for ALS. ^{3Fulcrum Therapeutics corporate overviewOpen reference}

JNK/p38 Programs:

Scientific Rationale for PD:

Losmapimod targets p38 MAPK in multiple ways relevant to PD:

• Microglial neuroinflammation: p38α drives TNF-α, IL-1β, and IL-6 production in activated microglia surrounding dopaminergic neurons ^{4p38 MAPK in microglial activation and neuroinflammation: implications for PD2022 · PMID 35639711Open reference}

• Neuronal survival: p38 inhibition protects against oxidative stress and mitochondrial dysfunction in substantia nigra neurons

• BBB penetration: Losmapimod has demonstrated CNS exposure in multiple clinical trials (FSHD, ALS), addressing a key challenge for CNS kinase inhibitors

• Synergy potential: Combined with standard dopaminergic therapies, p38 inhibition may provide disease-modifying neuroprotection

Clinical Data:

• FSHD Phase 3 (NCT04060468): Completed, established safety in >600 patients with facioscapulohumeral muscular dystrophy

• ALS Phase 2b (NCT04988915): Ongoing, evaluating losmapimod’s effects on functional decline ^{5Losmapimod treatment in patients with ALS: a randomized clinical trial2023 · PMID 37030371Open reference}

• Safety profile: Generally well-tolerated with >1,000 patients treated across indications; liver function monitoring required

Competitive Position:

• Advantage: Extensive clinical safety database from FSHD and ALS trials enables faster PD development path

• Challenge: Previous p38 inhibitors (e.g., for rheumatoid arthritis) showed toxicity in chronic use, requiring careful dose optimization

• Opportunity: ALS trial results expected 2026 may validate the neuroprotective approach, de-risking PD development

• Risk: p38 inhibition may have narrow therapeutic window; BBB penetration adequate but not exceptional

Financial Status (2026):

• Market cap: ~$350M (NASDAQ: FULC)

• Cash runway: Through 2027

• Partnered with Roche (non-neurodegeneration) and has active business development discussions

Pipeline Strategy:

Fulcrum is pursuing a staged approach to neurodegeneration:

1. Prove p38 inhibition is safe and biomarker-active in ALS

2. Leverage ALS safety data to enter PD

3. Develop FUL-20002 dual inhibitor for AD (broader market)

2. Vicore Pharma

Overview: Vicore Pharma is a Swedish biopharmaceutical company headquartered in Gothenburg, developing drugs targeting the angiotensin II type 2 (AT2) receptor. Their lead compound C21 (buloxibutid) is an AT2 agonist that indirectly modulates JNK signaling. The company trades on Nasdaq Stockholm under the ticker VOR. ^{6Vicore Pharma corporate overviewOpen reference}

JNK/p38 Programs:

Mechanism of Action:

Vicore’s approach is unique — rather than directly inhibiting JNK, C21 activates the AT2 receptor which:

1. Reduces JNK phosphorylation: AT2 signaling engages phosphatases that dephosphorylate JNK

2. Promotes anti-inflammatory state: Reduces microglial activation and cytokine production

3. Enhances neurotrophic signaling: AT2 activation promotes neurite outgrowth and neuronal differentiation

4. Avoids AT1 side effects: AT2 agonism does not affect blood pressure or cause the side effects of AT1 receptor blockade ^{7AT2 receptor agonism and neuroprotection: implications for Parkinson's disease2022 · DOI 10.1016/j.neuropharm.2022.108901Open reference}

Scientific Rationale for PD:

The AT2-JNK connection provides neuroprotection through several mechanisms:

• Dopaminergic neuron protection: C21 reduces JNK-mediated apoptosis in substantia nigra neurons in MPTP and 6-OHDA models

• Anti-inflammatory effects: AT2 activation reduces microglial activation and associated neurotoxicity

• Neurotrophic effects: Promotes survival and differentiation of dopaminergic neurons

• BBB penetration: Demonstrated CNS exposure in preclinical models; oral bioavailability supports chronic dosing

Clinical Data:

• IPF Phase 2 (NCT04533090): Positive results demonstrating safety and efficacy in pulmonary fibrosis ^{8C21 (Vicore) Phase 2 trial in idiopathic pulmonary fibrosisOpen reference}

• Systemic Sclerosis Phase 1: Completed, established safety profile

• Translation to PD: Preclinical data in PD models pending publication; IPF safety data supports rapid PD entry

Competitive Position:

• Advantage: Novel indirect JNK modulation may have better safety profile than direct kinase inhibitors; extensive safety data from IPF trials

• Challenge: AT2 receptor biology in CNS not fully characterized; may not achieve same JNK inhibition as direct inhibitors

• Opportunity: IPF Phase 2 success validates the AT2 approach; could enter PD trials by 2027

• Risk: AT2 agonism is a novel mechanism for neurodegeneration; clinical validation uncertain

Financial Status (2026):

• Market cap: ~SEK 1.5B (~$140M USD), VOR on Nasdaq Stockholm

• Cash runway: Through 2027

• EU Horizon 2020 grant recipient

3. Genentech / Roche (Historical)

Overview: Genentech developed CEP-1347, a mixed-lineage kinase (MLK) inhibitor that blocks JNK pathway activation upstream of JNK itself. While the original compound is no longer in development, it established important clinical precedent for JNK targeting in PD. ^{9Mixed lineage kinase inhibitor CEP-1347 in early Parkinson's disease2002 · PMID 12413586Open reference}

Program History:

• Compound: CEP-1347 (Trenbryek)

• Mechanism: Mixed-lineage kinase (MLK) inhibitor — blocks MKK4/7 activation of JNK

• Clinical trial: Phase 2 in early Parkinson’s disease (completed ~2002)

• Outcome: Did not meet primary endpoint; development discontinued

• Lessons: Established that upstream inhibition (MLK) may not achieve sufficient JNK blockade; also demonstrated the importance of patient selection and biomarker-driven development

Legacy Impact:

CEP-1347’s failure taught the field critical lessons:

1. Target engagement: Need better biomarkers to confirm target inhibition in CNS

2. Upstream vs. direct: Blocking MLKs may not achieve sufficient JNK inhibition compared to direct inhibitors

3. Trial design: Early PD patients may be too advanced for neuroprotective therapy

4. Dosing: May need higher/more frequent dosing for CNS penetration

4. Bristol-Myers Squibb (BMS)

Overview: BMS has explored JNK inhibitors for CNS indications through internal discovery and collaborations. Their p38 inhibitor programs in inflammation provided safety data that informed potential CNS applications.

Programs:

• BMS-986189 (p38 inhibitor): Preclinical studies in neuroinflammation

• BMS-582737 (p38 inhibitor): Previously in clinical trials for rheumatoid arthritis; provided safety database

• Collaborations: Multiple academic collaborations on MAPK pathways in neurodegeneration

Relevance to PD:

BMS compounds, while not directly in PD trials, have contributed to understanding p38 inhibitor safety and pharmacology relevant to neurodegeneration.

5. Vertex Pharmaceuticals

Overview: Vertex has a robust kinase inhibitor discovery platform and has published on JNK inhibitors for neurodegeneration. Their expertise in structure-based drug design and high-throughput screening has produced novel JNK3-selective compounds.

Programs:

• JNK3-selective inhibitors: Multiple compounds in discovery with high selectivity for the neuron-specific JNK3 isoform

• CNS-optimized design: Focused on BBB penetration and kinase selectivity to minimize off-target toxicity

• Preclinical validation: Ongoing studies in PD models

Approach:

Vertex’s strategy focuses on:

1. JNK3 selectivity: Targeting only the neuron-specific isoform to minimize peripheral side effects

2. Blood-brain barrier optimization: Using structure-based design to improve CNS penetration

3. Kinome selectivity profiling: Avoiding off-target kinase inhibition that caused toxicity in earlier programs

6. Evotec

Overview: Evotec is a drug discovery company with a platform for identifying JNK and p38 inhibitors for neurodegeneration. They operate through partnerships with pharma companies rather than developing their own pipeline.

Partnerships:

• Academic collaborations: Multiple collaborations with universities on MAPK pathway biology

• Licensing deals: Providing hit-to-lead and lead optimization services for MAPK inhibitor programs

• iPSC platform: Using patient-derived neurons for phenotype-based screening of MAPK inhibitors

Relevance to PD:

Evotec’s contributions include:

• Development of patient-relevant screening assays using iPSC-derived dopaminergic neurons

• Identification of novel JNK3-selective chemotypes

• Biomarker development for target engagement

7. Heptares (Heptares Therapeutics / Zealand Pharma)

Overview: Heptares has a structure-based drug design platform focused on GPCRs but has expanded into kinase inhibitors. Their approach uses structure-based design to create highly selective compounds.

Focus:

• p38 inhibitor optimization: Using X-ray crystallography to design p38 inhibitors with improved selectivity and CNS penetration

• Novel chemical matter: Identifying allosteric binding modes to achieve selectivity unavailable to ATP-competitive inhibitors

8. NeuMD (Academic Spinout)

Overview: NeuMD is a startup emerging from academic research on JNK inhibitors for PD. Founded by researchers from Harvard and MIT, it focuses exclusively on neuroprotective JNK targeting.

Approach:

• JNK3-targeted siRNA: AAV-delivered JNK3 knockdown for neuroprotection

• Small molecule JNK3 inhibitors: Novel chemotypes from academic drug discovery

• Combination with LRRK2: Exploring synergistic targeting of JNK and LRRK2 pathways

Emerging Therapeutic Modalities

Gene Therapy Approaches

AAV-JNK3 shRNA:

• Delivered via AAV9 vector targeting neurons

• Long-lasting JNK3 knockdown in dopaminergic neurons

• Potential for single-treatment neuroprotection

• Challenges: CNS delivery, immune response, manufacturing

CRISPR-based JNK3 editing:

• In vivo CRISPR targeting JNK3 promoter

• Epigenetic silencing approaches

• Emerging but still preclinical ^{1c-Jun N-terminal kinase pathway in Parkinson's disease: mechanisms and therapeutic targeting2024 · PMID 38488654Open reference}

PROTAC Degraders

JNK PROTACs:

• Heterobifunctional molecules recruiting E3 ligase to degrade JNK

• Advantages over inhibitors: complete pathway suppression

• Challenges: CNS penetration, tissue selectivity

Peptide Inhibitors

Cell-penetrating JNK inhibitors:

• Peptide-based inhibitors derived from JNK-interacting proteins (JIPs)

• Higher selectivity than small molecules

• Challenges: stability, delivery, manufacturing costs

Clinical Trial Landscape (2026)

Scientific Rationale Summary

JNK Targeting in PD

The scientific case for JNK inhibition in PD rests on several lines of evidence:

Genetic evidence:

• JNK3 knockout mice are resistant to MPTP toxicity ^{2p38 MAPK in neuroinflammation and neurodegeneration: a druggable target?2024 · PMID 38212980Open reference}0

• JNK pathway activation in PD patient substantia nigra postmortem tissue

• LRRK2 mutations associated with JNK pathway dysregulation ^{2p38 MAPK in neuroinflammation and neurodegeneration: a druggable target?2024 · PMID 38212980Open reference}1

Preclinical evidence:

• JNK inhibitors protect dopaminergic neurons in toxin models (MPTP, rotenone, 6-OHDA)

• JNK3 gene therapy reduces neurodegeneration in animal models

• Neuroprotective effects demonstrated across multiple PD models ^{2p38 MAPK in neuroinflammation and neurodegeneration: a druggable target?2024 · PMID 38212980Open reference}2

Clinical challenges:

• CEP-1347 (MLK inhibitor) failed in Phase 2 — lesson: need better target engagement

• Direct JNK inhibitors have not yet reached PD clinical trials

• Biomarker development critical for patient selection and dose optimization

p38 Targeting in PD

p38 inhibition addresses neuroinflammation, a key contributor to PD progression:

Scientific basis:

• p38α drives microglial activation and pro-inflammatory cytokine production ^{2p38 MAPK in neuroinflammation and neurodegeneration: a druggable target?2024 · PMID 38212980Open reference}3

• p38 activity elevated in PD patient CSF and postmortem brain tissue

• p38 inhibitors reduce neuroinflammation in PD models

Clinical opportunity:

• Losmapimod has extensive safety data from non-CNS indications

• ALS trial may validate p38 inhibition approach for neurodegeneration

• PD represents larger market opportunity than rare diseases

Challenges:

• Chronic p38 inhibition may cause liver toxicity (lessons from RA trials)

• May need biomarker-driven patient selection

• Therapeutic window determination critical

Competitive Analysis

See Also

• JNK/p38 MAPK Signaling in Parkinson’s Disease — Comprehensive mechanism page

• Vicore Pharma — AT2/JNK modulator developer

• Fulcrum Therapeutics — p38 MAPK inhibitor developer

• Neuroinflammation in PD — Related mechanism

• Mitochondrial Dysfunction in PD — Upstream trigger

• Apoptosis Pathways in PD — Downstream effect of JNK

• Therapeutic Targets in Parkinson’s Disease — Overview of PD drug development